Astellas Pharma ADR (ALPMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
| 12-2014 | 09-2014 | 06-2014 | 03-2014 | 12-2013 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 1,422,230 | 985,642 | 492,724 | 1,184,000 | N/A |
| Depreciation Amortization | 423,034 | 301,690 | 151,439 | 624,000 | N/A |
| Accounts receivable | -384,692 | 15,821 | 44,600 | N/A | N/A |
| Accounts payable and accrued liabilities | 55,528 | 160,618 | 44,835 | N/A | N/A |
| Other Working Capital | -817,810 | -350,160 | -244,853 | -578,000 | N/A |
| Other Operating Activity | 661,848 | -154,733 | 105,654 | 850,000 | 0 |
| Operating Cash Flow | $1,360,137 | $958,877 | $594,399 | $2,080,000 | $N/A |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -62,295 | -36,998 | -19,806 | -200,000 | N/A |
| Net Acquisitions | N/A | N/A | N/A | 181,000 | N/A |
| Purchase Of Investment | -28,389 | -1,824 | -333 | N/A | N/A |
| Sale Of Investment | 35,939 | 37,872 | 15,161 | N/A | N/A |
| Purchase Sale Intangibles | -361,346 | -161,885 | -112,886 | N/A | N/A |
| Other Investing Activity | -369,917 | -157,248 | -114,043 | -242,000 | 0 |
| Investing Cash Flow | $-424,662 | $-158,198 | $-119,021 | $-261,000 | $N/A |
| Cash Flows From Financing Activities | |||||
| Common Stock Repurchased | -264,106 | -288,096 | -294,069 | N/A | N/A |
| Dividend Paid | -546,885 | -299,866 | -306,113 | -569,000 | N/A |
| Other Financing Activity | -4,981 | -3,322 | -1,852 | -299,000 | 0 |
| Financing Cash Flow | $-815,971 | $-591,283 | $-602,034 | $-868,000 | $N/A |
| Exchange Rate Effect | 290,875 | 78,326 | -53,263 | 276,000 | N/A |
| Beginning Cash Position | 3,444,091 | 3,757,190 | 3,835,465 | 2,572,000 | N/A |
| End Cash Position | 3,854,470 | 4,044,912 | 3,655,547 | 3,800,000 | N/A |
| Net Cash Flow | $410,379 | $287,722 | $-179,918 | $1,228,000 | $N/A |
| Free Cash Flow | |||||
| Operating Cash Flow | 1,360,137 | 958,877 | 594,399 | 2,080,000 | N/A |
| Capital Expenditure | -109,296 | -82,445 | -52,410 | N/A | N/A |
| Free Cash Flow | 1,250,841 | 876,432 | 541,989 | 2,080,000 | 0 |